Ex vivo drug sensitivity profiling‐guided treatment of a relapsed pediatric mixed‐phenotype acute leukemia with venetoclax and azacitidine

Gonzales, Fanny; Guilmatre, Audrey; Barthélémy, Adeline; Lapillonne, Hélène; Pottier, Nicolas; Leverger, Guy; Petit, Arnaud; Cheok, Meyling

doi:10.1002/pbc.29678

Cited by 4 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from those early-phase trials, the available literature discussing VTX in pediatric/AYA patients with hematologic malignancies contains a couple of single-institution reports [53][54][55][56][57][58][59] (Table 3) or multicenter retrospective analyses [60][61][62][63][64][65][66]. Recent studies support the usage of VTX-containing regimens in myeloid malignancies, especially as a linking therapy for allogeneic hematopoietic stem cell transplantation (HSCT) [60][61][62][63].…”

Section: Other Studies On Venetoclax Combination Therapies In Amlmentioning

confidence: 99%

Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies

Leśniak,

Lipniarska,

Majka

et al. 2023

IJMS

View full text Add to dashboard Cite

Venetoclax is a strongly effective B-cell lymphoma-2 inhibitor (BCL-2) with an ability to selectively restore the apoptotic potential of cancerous cells. It has been proven that in combination with immunotherapy, targeted therapies, and lower-intensity therapies such as hypomethylating agents (HMAs) or low-dose cytarabine (LDAC), the drug can improve overall outcomes for adult patients with acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM), amongst other hematological malignancies, but its benefit in pediatric hematology remains unclear. With a number of preclinical and clinical trials emerging, the newest findings suggest that in many cases of younger patients, venetoclax combination treatment can be well-tolerated, with a safety profile similar to that in adults, despite often leading to severe infections. Studies aim to determine the activity of BCL-2 inhibitor in the treatment of both primary and refractory acute leukemias in combination with standard and high-dose chemotherapy. Although more research is required to identify the optimal venetoclax-based regimen for the pediatric population and its long-term effects on patients’ outcomes, it can become a potential therapeutic agent for pediatric oncology.

show abstract

Section: Other Studies On Venetoclax Combination Therapies In Amlmentioning

confidence: 99%

Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies

Leśniak,

Lipniarska,

Majka

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…MPAL accounts for 2-4% of acute leukemia, in which the blasts express markers from more than one lineage, 5,6 with poor prognosis even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). 7 B/T MPAL is exceptionally rare, consisting of 5% of MPAL. 8 As a specific marker for myeloid lineage, MPO is seldomly expressed in lymphoid leukemia, let alone in B/T MPAL.…”

mentioning

confidence: 99%

Myeloperoxidase‐positive bilineal mixed phenotype acute leukemia (B/T) with chromosome copy neutral loss of heterozygosity exhibits simultaneous diffuse leukemic infiltrations in the lung, bone, and endorachis

Huang

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Antineoplastics

2022

Reactions Weekly

View full text Add to dashboard Cite

Ex vivo drug sensitivity profiling‐guided treatment of a relapsed pediatric mixed‐phenotype acute leukemia with venetoclax and azacitidine

Cited by 4 publications

References 13 publications

Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies

Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies

Myeloperoxidase‐positive bilineal mixed phenotype acute leukemia (B/T) with chromosome copy neutral loss of heterozygosity exhibits simultaneous diffuse leukemic infiltrations in the lung, bone, and endorachis

Antineoplastics

Contact Info

Product

Resources

About